Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The eukaryotic ribosome, frequently referred to as the host cell ribosome in the context of viral infection and toxicology, is a massive ribonucleoprotein complex responsible for all cytoplasmic protein synthesis (Nature, 2011). It consists of a small 40S subunit, which decodes mRNA, and a large 60S subunit, which catalyzes peptide bond formation via its peptidyl transferase center (Science, 2010). While many antibiotics target bacterial ribosomes, the host ribosome is the specific target of certain therapeutic agents like omacetaxine mepesuccinate, used to treat chronic myeloid leukemia by inhibiting the initial step of translation (Blood, 2012). It is also the target of potent ribosome-inactivating proteins (RIPs) such as ricin and Shiga toxin, which irreversibly damage the 28S rRNA to arrest protein synthesis (Journal of Biological Chemistry, 2001). Furthermore, the host ribosome is a critical site of conflict during viral infections, as viruses like SARS-CoV-2 employ specialized proteins to hijack or obstruct the machinery to prioritize viral protein production (Science, 2020). Due to its essential role in cell viability, the host ribosome represents a high-stakes target where therapeutic index and selectivity are paramount.
Inhibition of protein synthesis by binding to the A-site cleft of the peptidyl transferase center (PTC) to prevent aminoacyl-tRNA positioning, or through enzymatic depurination of the sarcin/ricin loop in the 28S rRNA which prevents elongation factor binding (PubMed, 2012; JBC, 2001).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic ribosome (80S ribosome) (80S ribosome).